Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections -

TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced positive results from a large prospective trial conducted for prevention of respiratory syncytial virus (RSV). The trial compared motavizumab, the investigational monoclonal antibody (MAb) also known as Numax(R), with Synagis(R) (palivizumab), the standard of care for preventing RSV hospitalization in high-risk infants. In the Phase 3 study involving 6,635 pre-term infants at high risk for RSV, with a primary endpoint of non- inferiority, motavizumab demonstrated overall 26-percent fewer RSV hospitalizations compared with Synagis (p<0.01 for non-inferiority). Additionally, motavizumab demonstrated a statistically significant 50 percent reduction in the incidence of RSV-specific medically attended outpatient lower respiratory infections (LRIs) (p<0.01) compared with Synagis. These findings were presented today in a poster entitled, Phase 3 Trial of Motavizumab, an Enhanced Potency RSV-Specific MAb for the Prevention of Serious RSV Disease in High-Risk Infants, at the Pediatric Academic Societies' Annual Meeting in Toronto, Canada.

"As RSV continues to be the leading cause of lower respiratory tract infections in infants in the United States, we are very encouraged by the results of this Phase 3 trial, which suggest that motavizumab may help to reduce the chance that our most vulnerable babies will have serious RSV disease," said Edward M. Connor, M.D., chief medical officer and executive vice president. "Data from the study showed that motavizumab was statistically superior to Synagis for the secondary endpoint of outpatient medically attended LRI caused by RSV, and thus may reduce the overall burden of RSV disease compared to the current stan
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/19/2014)... Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... in the U.S. and XIAPEX ® in the ... will present a corporate overview at the 21 st ... The presentation will take place on Friday, September 26, ... in New York, NY . A live ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... at American Society of Clinical ... Oncology Annual Meeting, PRINCETON, ... updated long-term follow-up and overall,survival (OS) results from a Phase 2 ... (DTIC) where 11.4%, or 4 of,35 patients, were still alive at ...
... Noted in Management of Transplant Recipients with Cancer, ... of,immunosuppression in post-transplant patients with cancer is challenging.,Clinicians ... effectively while,simultaneously monitoring the impact of chemotherapeutic agents ... improving management of such patients will be,presented today ...
Cached Medicine Technology:Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 2Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 3Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 4Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity 2
(Date:9/20/2014)... York, New York (PRWEB) September 20, 2014 ... power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological ... that yet another insurer has announced plans to ... statement posted on its website last month, Harrisburg, ... procedures effective November 1, 2014. The insurer said ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee ... is re-visiting that advice and changing his stance after considering ... have on oral health. “There’s good news and great news,” ... beneficial in protecting against gum disease, and red wine can ... was from the September 2014 issue of Boston University ...
(Date:9/20/2014)... September 20, 2014 Earlier this week, Home ... may have had their credit card information pilfered by hackers, ... a slew of headline articles like this one ... only eye opening numbers. , “Most people tend to ... like it’s a way to score a game,” says Joe ...
(Date:9/20/2014)... The Arizona Advanced Manufacturing ... National Manufacturing Day by opening its doors to the ... additive manufacturing labs will be offered between 10 a.m. ... Southern and Dobson campus (1833 W. Southern Ave, Mesa, ... , The AzAMI at MCC was established in the ...
(Date:9/20/2014)... 2014 The children of Branches now ... active play they need. An empty lot at the ... Campus was transformed into a kid-designed playspace in less ... from Branches (@BranchesFL), ESPN (@TeamESPN), Disney (@CitizenDisney), area residents ... a playground is more than a playground. It’s a ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 3Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 4
... MiLife Coaching Limited,announces the publication of their third ... weight management coaching system to boost employee,health and ... , MiLife is an ... physical activity management system. It incorporates biofeedback and,the ...
... season prompts tips on how to avoid most common cause ... -- If you didn,t know better, you could confuse carbon ... U.S. Environmental Protection Agency has a new fact sheet out ... deaths and 15,000 visits to the emergency room caused each ...
... Eklin Medical Systems, a leading,provider of digital ... and practice management software (VIA) for veterinary,care, introduced ... North American,Veterinary Conference being held in Orlando, January ... economical solution for digital imaging based on Eklin,s ...
... INSM ), a developer of follow-on ... dedicated to the development of, diagnosis and prevention of ... that the European Medicines Agency (EMEA) has granted Premacure ... mecasermin rinfabate, for the prevention of retinopathy of prematurity ...
... Varian, Inc.,(NasdaqGS: VARI) plans to release its financial ... Pacific Time (PT) on Wednesday February 4,2009. A live ... to,review those quarterly results is scheduled to follow at ... That live webcast can be accessed from Varian, ...
... 21 Horphag Research, exclusive worldwide,suppliers of Pycnogenol(R) ... earned the 2008 Frost & Sullivan North American ... This award, presented,last week at Frost & Sullivan,s ... Research,s efforts in conducting numerous research projects,over the ...
Cached Medicine News:Health News:MiLife Proven to Boost Vitality of Unilever Employees Using Smart Affordable Technology 2Health News:Eklin Launches New RapidStudy(TM) CDx Digital Radiography System at NAVC 2Health News:Eklin Launches New RapidStudy(TM) CDx Digital Radiography System at NAVC 3Health News:Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants 2Health News:Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants 3Health News:Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award 2Health News:Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award 3
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
... Autostat™II Rheumatoid Factor IgM enzyme linked immunosorbent ... (RF IgM). Enzyme-linked immunosorbent assay method for ... Factor in human serum. The results of ... as an aid in the diagnosis of ...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
... The GALILEI Dual Scheimpflug Analyzer is a ... and three dimensional analysis of the anterior ... Channel Scheimpflug Camera and a Placido Disk. ... technologies: Placido imaging furnishes high accuracy curvature ...
Medicine Products: